Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-TXNDC5, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TXNDC5 also known as Thioredoxin Domain-Containing Protein 5 is an endoplasmic reticulum-resident protein with a molecular mass of approximately 48 kDa. This protein functions as a disulfide isomerase assisting in the formation and rearrangement of disulfide bonds in newly synthesized proteins. Researchers note its high expression in tissues such as the liver lung and heart where protein folding demands are significant. Due to its involvement in protein folding TXNDC5 maintains cellular homeostasis and assists in proper protein assembly.
Biological function summary
TXNDC5 contributes to the oxidative folding of proteins within the endoplasmic reticulum. The protein does not act alone but as part of a larger complex involving other chaperones and foldases that together ensure protein quality control. TXNDC5 interfaces with the redox system impacting the oxidative environment necessary for correct protein folding. By contributing to this complex system TXNDC5 helps prevent the accumulation of misfolded proteins and maintains the integrity of cellular function.
Pathways
TXNDC5 plays a role in the protein folding pathway which is vital to maintaining cellular stability. In addition its involvement in the response to unfolded protein responses signifies its importance in stress-related pathways. TXNDC5 often interacts with other proteins such as PDI (Protein Disulfide Isomerase) and Calreticulin which are also important in protein folding and cellular stress responses. These pathways are essential for adapting to changes in protein synthesis demands and mitigating the effects of cellular stress.
TXNDC5 has associations with conditions such as rheumatoid arthritis and certain cancers. Aberrant expression levels of TXNDC5 correlate with increased inflammatory responses in rheumatoid arthritis indicating its role in disease progression. In cancer overexpression of this protein has been observed suggesting a potential role in tumor growth and survival. Additionally TXNDC5 interacts with proteins like Hsp70 (Heat Shock Protein 70) which also plays a role in these disorders by assisting in protein folding under stress conditions thereby potentially influencing disease outcomes.
